Drug intelligence / Profile preview

Zp17

Development stage
Preclinical
Lead developer
Henan Normal University
Modality
PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01

Overview

Zp17: sourced facts only. name: "Zp17 illustrated superior STING degradation activity and exhibited significantly lower cytotoxicity compared to SP23 in vitro." [PMID:42372458]; target: "Zp17 illustrated superior STING degradation activity and exhibited significantly lower cytotoxicity compared to SP23 in vitro." [PMID:42372458]; developer: "Collaborative Innovation Center of Henan Province for Green Manufacturing of Fine Chemicals, Key Laboratory of Green Chemical Media and Reactions, Ministry of Education, Henan Key Laboratory of Organic Functional Molecule and Drug Innovation, School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, Henan 453007, PR China." [PMID:42372458]; modality: "Collectively, compound Zp17 warrants further investigation as PROTAC degrader of STING." [PMID:42372458]; stage: "In mouse acute kidney injury (AKI) model, Zp17 effectively alleviated renal function impairment induced by cisplatin." [PMID:42372458]

02

Targets

STING (Stimulator of interferon genes protein)

Beyond the preview

Go deeper on Zp17.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zp17.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call